BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 23926199)

  • 1. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
    Hollstein M; Moriya M; Grollman AP; Olivier M
    Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
    Rosenquist TA; Grollman AP
    DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
    Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
    Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics traces carcinogen fingerprints.
    Lee W; Ladanyi M
    Sci Transl Med; 2013 Aug; 5(197):197fs31. PubMed ID: 23926198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aristolochic acid-associated urothelial cancer in Taiwan.
    Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
    Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
    Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aristolochic Acid in the Etiology of Renal Cell Carcinoma.
    Hoang ML; Chen CH; Chen PC; Roberts NJ; Dickman KG; Yun BH; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1600-1608. PubMed ID: 27555084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
    Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
    Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid.
    Castells X; Karanović S; Ardin M; Tomić K; Xylinas E; Durand G; Villar S; Forey N; Le Calvez-Kelm F; Voegele C; Karlović K; Mišić M; Dittrich D; Dolgalev I; McKay J; Shariat SF; Sidorenko VS; Fernandes A; Heguy A; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1873-81. PubMed ID: 26383547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
    Nault JC; Letouzé E
    Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
    Aydin S; Ambroise J; Cosyns JP; Gala JL
    Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
    Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.
    Yang HY; Yang CC; Wu CY; Wang LJ; Lu KL
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.